- Prev close
- $166.89
- Day range
- $164.00 – $169.06
- From 52-wk high
- -5.5%
Gilead’s 4.0% decline looks more stock-specific than market-driven, with the shares sliding even as the S&P 500 rose 1.7% and the Nasdaq 100 rose 1.0%. The broader setup is mixed: 6.5% revenue growth and a 20.9 forward PE support the case, but the move came after earnings and pipeline headlines that keep attention on execution.
GILD
GILEAD SCIENCES INC
As of Nov 5, 2026
58/100
Worth keeping an eye onHealth ScoreMove driver
The primary driver looks stock-specific, not the market. GILD fell 4.0% while the S&P 500 rose 4.0% and the Nasdaq 100 rose 4.0%, and its peers were only down 4.0% for ABBV and 3.8% for AMGN. The intraday path also matters: it opened at $174.54, traded as high as $176.58, then faded to a $167.57 close, which points to sellers taking control after an early bid rather than a simple index-led drift.
Volatility check
This is more than ordinary index noise, but it is not paired with obvious operating deterioration. The company still shows revenue growth of 6.5% TTM and 6.8% in the latest quarter, with gross margin at 80.0%, while the forward PE is 20.9 and beta is 0.38, which means the shares usually move less than the market. The profitability picture is uneven, though, because operating margin is -7.6% and net margin is -12.5%, so the stock is still pricing in a lot of future improvement. That makes a 4.0% drop understandable as a post-event re-rating, even if the underlying growth trend remains intact.
Earnings preview
The facts do not give a next earnings date, so the upcoming report date is not available this period. The most recent earnings update cited third quarter 2026 revenue of US$8.3b, raised full year product sales guidance, and a larger projected GAAP loss tied to sizeable acquired R&D charges, so the market will likely focus on three items: whether product sales guidance still holds, whether the revenue pace around 6.5% TTM and 6.8% last quarter is sustained, and how much the acquired R&D burden continues to weigh on GAAP profitability. The fact set does not include a reliable prior-print trading pattern, so I won’t infer one from limited headlines.
This report is for informational and educational purposes only. It does not constitute financial, investment, tax, or legal advice. The platform does not recommend buying or selling any security.
Track GILD with WhyIHold
Get a plain-English explanation the next time GILEAD SCIENCES INC makes a big move — so you know whether it's benign or worth your attention.